[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[$112bn](/topic/$112bn)

### Top Social Posts

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"#CLIG XXXX MT @TickerOfficial ✅$CLIG reports FuM increased by X% to $11.2bn. ✅EM and Listed Private Equity strategies outperformed benchmarks. ✅Opportunistic Value underperformed. RNS📸via @entrustTMF👍"  
[X Link](https://x.com/conkers3/status/1980172856857411639) [@conkers3](/creator/x/conkers3) 2025-10-20T07:22Z 10.4K followers, XXX engagements


"#CLIG reports FuM increased by X% to $11.2bn. EM and Listed Private Equity strategies outperformed benchmarks; Opportunistic Value underperformed"  
[X Link](https://x.com/TickerOfficial/status/1980152663606997341) [@TickerOfficial](/creator/x/TickerOfficial) 2025-10-20T06:02Z 1135 followers, XXX engagements


"IndiaUK ties: Starmer visit delivers tech trade & research pact roadmap to $112bn bilateral target by 2030"  
[X Link](https://x.com/AniketP24414553/status/1976522623547998386) [@AniketP24414553](/creator/x/AniketP24414553) 2025-10-10T05:38Z X followers, XX engagements


"Daiichi Sankyo dosed over 1000 patients with Exatecan in clinical trials but ultimately it failed in the clinic. Today they use Deruxtecan (basically a watered down version of Exatecan) in their blockbuster ADC drug Enhertu Enhertu is expected to generate $11.2bn by 2030 per year. Imagine what AVA6103 could do with a much wider total addressable market (TAM) vs Enhertu which is limited by HER2 expression. Avacta's PreCISION uses FAP which is fortunately present in XX% of solid tumours (4/5)"  
[X Link](https://x.com/AM231982/status/1975852734940131810) [@AM231982](/creator/x/AM231982) 2025-10-08T09:16Z XXX followers, XXX engagements